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ABSTRACT 41	
Hepatitis C virus (HCV) infection causes 500,000 deaths annually, associated with end-stage 42	
liver diseases.  Investigations of the HCV life cycle widened the knowledge in virology, and 43	
here we discovered that two piperazinylbenzenesulfonamides inhibit HCV entry into liver 44	
cells. The entry process of HCV into host cells is a complex process, not fully understood, but 45	
characterized by multiple spatially and temporally regulated steps involving several known 46	
host factors. Through a high-content virus-infection screening analysis with a library of 1,120 47	
biologically active chemical compounds, we identified SB258585, an antagonist of the 48	
serotonin receptor 6 (5-HT6), as a new inhibitor of HCV entry in liver-derived cell lines, as 49	
well as in primary hepatocytes. A functional characterization suggested a role for this 50	
compound, as well as for the compound SB399885 sharing a similar structure, as inhibitors of 51	
a late HCV entry step, modulating the localization of the co-receptor tight junction protein 52	
claudin 1 (CLDN1), in a 5-HT6 independent manner. Both chemical compounds induced an 53	
intracellular accumulation of CLDN1, reflecting export impairment. This regulation 54	
correlated with the modulation of protein kinase A (PKA) activity. The PKA inhibitor H89 55	
fully reproduced these phenotypes. Furthermore, PKA activation resulted in increased 56	
CLDN1 accumulation at the cell surface. Interestingly, increase of CLDN1 recycling did not 57	
correlate with an increased interaction with CD81 or HCV entry. These findings reinforce the 58	
hypothesis of a common pathway shared by several viruses, which involves G-protein 59	
coupled receptor -dependent signaling in late steps of viral entry. 60	
IMPORTANCE 61	
The HCV entry process is highly complex and important details of this structured event are 62	
poorly understood. By screening a library of biologically active chemical compounds, we 63	
identified two piperazinylbenzenesulfonamides as inhibitors of HCV entry. The mechanism 64	
of inhibition was not through previously described activity of these inhibitors as antagonists 65	
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of the serotonin receptor 6, but instead through modulation of PKA activity in a 5-HT6 66	
independent manner, as proven by the lack of 5-HT6 in liver. We thus highlighted the 67	
involvement of PKA pathway in modulating HCV post-binding step entry and in the 68	
recycling of the tight junction protein claudin-1 (CLDN1) towards the cell surface. Our work 69	
underscores once more the complexity of HCV entry steps and suggests a role for PKA 70	
pathway as regulator of CLDN1 recycling, having an impact on both cell biology and 71	
virology. 72	
 73	
INTRODUCTION 74	
Virus entry into specific host cells is a tightly regulated multistep process. Among 75	
known viruses, the liver pathogen hepatitis C virus (HCV), which causes 500,000 deaths 76	
annually, has probably one of the most complex multistep entry processes involving a 77	
growing number of cellular entry factors (1). Furthermore, the regulation of trafficking of 78	
these proteins provides an additional level of complexity. Although the involvement of a large 79	
number of host factors has been demonstrated in HCV entry, several gaps remain in our 80	
comprehension of this process. Further functional studies are therefore needed to better 81	
understand the regulation of the early steps of the HCV life cycle.  82	
After binding to attachment factors such as heparan sulfate proteoglycans and the low 83	
density lipoprotein (LDL) receptor, HCV particles specifically bind to the entry receptors 84	
scavenger receptor BI (SRB1) and CD81 tetraspanin (2). HCV binding to CD81 induces a 85	
diffusion of this virion-tetraspanin complex on the plasma membrane, towards the sites of 86	
viral internalization (3). Only a specific fraction of CD81, located outside of tetraspanin-87	
enriched areas, is involved in HCV entry (4) through its interaction with the tight junction 88	
protein claudin 1 (CLDN1) (5–7). Importantly, CD81-CLDN1 interaction is a major event 89	
driving HCV endocytosis (8). Among other identified host factors involved in HCV entry (2), 90	
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occludin (OCLN), another tight-junction protein, also plays a major role in a late step of HCV 91	
entry through an unknown mechanism (9). Together, these observations indicate that tight 92	
junction proteins play a central role in HCV entry. However, the regulation of these proteins 93	
in the liver remains poorly understood and little information is available on CLDN1 94	
trafficking and its interplay with CD81 and OCLN both in infected and non-infected cells. 	95	
In this study, we implemented a high-content screening (HCS) approach using a 96	
library of chemical compounds to search for new regulators of HCV entry. We identified 97	
serotonin receptor 6 (5-HT6) antagonists SB258585 and SB399885 as inhibitors of a late step 98	
of HCV entry. More specifically, we showed a reduction of PKA activation upon treatment, 99	
in a 5-HT6-independent manner. We confirmed the involvement of PKA pathway in HCV 100	
entry and a role of its activation in CLDN1 export. Taken together, these data identify new 101	
inhibitors of HCV post-binding step and provide new findings in regulation of CLDN1 102	
transport and function. This work highlights once more the complexity of the HCV entry 103	
process proving that the presence of CLDN1 at the cell surface is not sufficient to mediate its 104	
interaction with CD81. This confirms the importance of the membrane environment and the 105	
need of the synergistic action of several receptors in HCV entry. 106	
 107	
RESULTS 108	
Identification of the 5-HT6 antagonist SB258585 as a new inhibitor of the HCV life 109	
cycle. 110	
To identify new cellular factors involved in the early steps of the HCV infectious 111	
cycle, we performed a HCS using a library of 1,120 biologically active chemical compounds. 112	
The screen was repeated using three different concentrations (1 µM, 10 µM and 20 µM) in 113	
Huh-7 cells infected with cell culture derived HCV (HCVcc) strain JFH1 (genotype 2a) (10, 114	
11). A re-infection experiment was performed as an additional filter to eliminate false-115	
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positive compounds (Supplemantal dataset S1). Compounds reducing the infection by at least 116	
45% compared to the average of DMSO wells affecting cell viability for less than 35% were 117	
considered as positive hits (Fig. 1A-C). Finally, we only retained compounds confirmed in the 118	
re-infection experiment and inhibiting HCV infection for at least two of the three tested 119	
concentrations (Fig. 1D and Table 1). According to these criteria, 20 compounds were 120	
selected. Nine of them had been previously described as having an inhibitory effect on HCV 121	
or targeting cellular pathways identified as important for HCV infection, thus validating our 122	
screen (12–16). Among the 11 remaining hits, we identified 5 compounds targeting serotonin 123	
(5-HT) receptors or transporters. Serotonin receptors constitute a class of 16 human receptors, 124	
none of which have ever been identified as host factor involved in the HCV infectious cycle. 125	
To identify the 5-HT receptor(s) playing a role in HCV infection, we searched the Tocriscreen 126	
Total library for all the compounds targeting in a more or less specific manner each of these 127	
receptors, in accordance with data available on the following databases: 128	
http://www.guidetopharmacology.org/ and http://stitch.embl.de (17). Interestingly, with only 129	
one exception, all the compounds targeting the serotonin receptor 6 (5-HT6) showed a dose-130	
response inhibitory effect on HCV JFH1 infection (Fig. 1E), in contrast to the compounds 131	
targeting other 5-HT receptors where, for most of them, only the highest concentration 132	
showed an inhibitory activity. Among the inhibitors of 5-HT6, SB258585 was identified as a 133	
hit according to the criteria of lack of cell toxicity and inhibition of infection chosen in the 134	
screen (Fig. 1F and Table 1).  135	
 136	
SB258585 inhibits HCV infection, down-regulating PKA activity independently of 5-137	
HT6 receptor. 138	
In order to confirm the inhibitory effect of 5-HT6 antagonist SB258585 on HCV viral 139	
cycle, kinetics of JFH1 infection were performed in the presence of this compound. The 140	
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maximum inhibitory effect of SB258585 was observed when the chemical compound was 141	
added during the inoculation of the virus (Fig. 2A), suggesting an effect on virus entry. As 142	
shown in Fig. 2B, the inhibition was not due to drug toxicity.  143	
5-HT6 receptor, mainly studied in the central nervous system, has not been 144	
characterized in the liver or hepatocyte. In order to determine its real involvement in HCV 145	
infection as a target of SB258585, we quantified its expression level in the liver. To do so, we 146	
compared its distribution by qRT-PCR in seventeen different human tissues. This analysis 147	
showed that 5-HT6 was highly expressed in brain tissues and intestine (Fig. 2C). It was also 148	
expressed in testis, while it was not detected in all the other tissues, including the liver (Fig. 149	
2C). Quantification of 5-HT6 mRNA in Huh-7 cells by qRT-PCR showed a DCt of around 18 150	
as compared to the housekeeping gene RPLP0, confirming an almost complete absence of 151	
detection of 5-HT6 in this hepatic cell line. Not surprisingly, we were unable to detect the 5-152	
HT6 protein by western blot and flow cytometry by using different antibodies (data not 153	
shown). This observation implies that the effect observed on HCV infection is probably not 154	
connected to 5-HT6.  155	
5-HT6 is a G-protein coupled receptor (GPCR), associated with a G alpha stimulatory protein 156	
(Gas). This Gas activates the adenylyl cyclase to produce cAMP, which in turn activates 157	
protein kinase A (PKA) (18). However, GPCR agonists and antagonists often show affinity 158	
for additional GPCR than the one specifically targeted. Therefore, we evaluated whether the 159	
presence of 5-HT6 antagonist leads to a regulation of the PKA pathway, likely through 160	
modulation of other GPCRs. We thus performed a western blot with an antibody specific for 161	
PKA phosphorylated substrates. The cell permeable inhibitor of cAMP-dependent protein 162	
kinase (PKA) H89 was used as a positive control. This compound is described to inhibit PKA 163	
by competitive binding to the ATP site on PKA catalytic subunit (19). As shown in Fig. 2D, 164	
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SB258585 reduced the phosphorylation level of PKA substrates in a similar manner as the 165	
PKA inhibitor H89. 166	
Therefore, our observations about the phosphorylation level of PKA substrates suggest 167	
that the off-target effect of SB258585 targets a factor involved in PKA activation, likely 168	
another GPCR coupled to a Gas protein.  169	
 170	
SB258585 and SB399885 inhibit a late step of HCV entry, altering cell surface 171	
localization of CLDN1. 172	
According to the kinetics shown in Fig. 2A, SB258585 seems to inhibit HCV entry. 173	
The inhibitory effect of SB258585 on HCV entry was then validated with the help of 174	
retroviral pseudo-particles harboring HCV envelope glycoproteins (HCVpp) from JFH1strain 175	
(genotype 2a) (Fig. 3A). SB258585 had no effect on adenovirus infection, indicating that this 176	
compound has not a global effect on viral entry (Fig. 3B). We also confirmed its inhibitory 177	
effect on primary human hepatocytes (PHHs) infected by HCV strain JFH1 (genotype 2a) 178	
(Fig. 3C) (20), as well as on 18 different JFH1-based Core-NS2 strain recombinants 179	
representing the six HCV major genotypes and important subtypes (Fig. 3D, Table 2) (21–180	
27).  181	
In order to better understand the mechanism of action of SB258585 as an inhibitor of 182	
HCV infection, we decided to test another characterized 5-HT6 antagonist, SB399885 which 183	
shares a very similar structure (Fig. 3F). The fact that both antagonists inhibit a common step 184	
of HCV infection (Fig. 2A, 3G-H) in the absence of their main targeted receptor, modulating 185	
PKA activity (Fig.2D) suggests that their common structure of 186	
piperazinylbenzenesulfonamides is likely responsible for a common off-target effect.  187	
To better identify the entry step targeted by these compounds, we performed a time-188	
of-addition assay, using proteinase K and bafilomycin A respectively as controls of early and 189	
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late step of viral entry. Proteinase K blocks viral internalization through proteolysis of viral 190	
particles exposed to the extracellular compartment, while Bafilomycin A blocks the 191	
endosomal acidification resulting in the inhibition of viral fusion (28). A comparison of 192	
SB258585 and SB399885 to the kinetics of proteinase K and Bafilomycin A treatment rather 193	
revealed an inhibition of a late step of the entry process (Fig. 3E, 3I). It is worth noting that 194	
the slight difference in the SB258585 curves obtained at 20µM and 100 µM was not 195	
statistically significant. 196	
Knowing that CD81-CLDN1 interaction is necessary for clathrin-dependent 197	
endocytosis of HCV particles (8), we analyzed the effect of these 198	
piperazinylbenzenesulfonamides on CD81-CLDN1 co-localization. A dose-dependent 199	
decrease of CD81-CLDN1 co-localization was observed after treatment with SB258585, as 200	
confirmed by determining the Pearson correlation coefficient (Fig. 4A-B). Furthermore, we 201	
observed a decrease of cell surface CLDN1 expression by flow cytometry analyses in non-202	
infected (Fig. 4C) and infected cells (data not shown) treated with SB258585. This could 203	
explain the alteration in CD81-CLDN1 co-localization. The same phenotype was also 204	
observed in cells treated with SB399885 (Fig. 4D). Furthermore, kinetic analyses revealed 205	
that the decrease of CLDN1 cell surface expression after SB258585 treatment is quite rapid 206	
and reversible (Fig. 4E-F). It is worth noting that this compound had no effect on the 207	
distribution of other major HCV entry co-receptors, including CD81 (Fig. 5). 208	
 209	
Alteration of cell surface expression of CLDN1 mediated by SB258585 is due to CLDN1 210	
intracellular accumulation. 211	
Decreased CLDN1 cell surface expression could be due either to CLDN1 degradation 212	
or intracellular accumulation. To answer this question, we first analyzed the total level of 213	
CLDN1 by western blot. Treatment of Huh-7 cells with SB258585 and SB399885 did not 214	
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affect the amount of CLDN1 (Fig. 4G), indicating that these compounds do not induce 215	
CLDN1 degradation. Instead, immunofluorescence analyses showed an intracellular 216	
accumulation of CLDN1 in the presence of SB258585 (Fig. 4H), confirmed by an increased 217	
co-localization with the intracellular markers TGN46 (Fig.4I), ERGIC53 and GM130 (data 218	
not shown). This intracellular accumulation could be due either to an increase in CLDN1 219	
endocytosis or to an alteration in CLDN1 export. To elucidate this, we used an internalization 220	
assay based on cell surface biotinylation to determine the kinetics of CLDN1 endocytosis in 221	
the presence or absence of the drug. As shown in Fig. 4J, CLDN1 endocytosis was maximal 222	
after 1h. The protein amount was comparable in DMSO or SB258585 treated cells, suggesting 223	
no alteration of CLDN1 endocytosis. Conversely, at later time points, biotinylated CLDN1 224	
disappeared in DMSO treated cells, suggesting that it had either been degraded or recycled to 225	
the cell surface, while it remained stored intracellularly in the presence of the compound. This 226	
is in agreement with the accumulation of CLDN1 detected by immunofluorescence (Fig. 4H). 227	
Since no change in total CLDN1 level was observed between DMSO and SB258585 228	
treatment (Fig. 4G), it is unlikely that endocytosed CLDN1 is degraded. Rather, CLDN1 must 229	
be recycled to the plasma membrane. Accumulation of intracellular CLDN1 observed after 230	
SB258585 treatment (Fig. 4H-J) suggests a defect of CLDN1 recycling and explains the 231	
decrease of CLDN1 at the cell surface. 232	
 233	
PKA inhibition affects HCV late entry step and regulates CLDN1 trafficking. 234	
To further confirm whether SB258585 inhibitory effect on HCV could be mediated by 235	
the PKA downstream pathway, we tested the effect of PKA inhibitor H89 on HCV infection. 236	
As reported by Farquhar and co-workers (29), we confirmed a dose-dependent inhibitory 237	
effect of this compound on both HCVpp and HCVcc of JFH1strain (genotype 2a) at non-toxic 238	
concentrations (Fig. 6A-C). We then used a time-of-addition assay with increasing 239	
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concentrations of H89, and our data indicated an inhibitory effect at a late step of HCV entry 240	
(Fig. 6D). Furthermore, as observed for the two piperazinylbenzenesulfonamides, H89 241	
treatment also induced a decrease of cell surface expression of CLDN1 (Fig. 6E) without 242	
affecting its total level of expression (Fig. 4G), but rather resulting in its intracellular 243	
accumulation (Fig. 4H-I). In addition, transfection of an exogenous catalytic subunit of PKA 244	
(PRKACA) followed by stimulation of PKA with the activator of adenylyl cyclase forskolin, 245	
also increased the phosphorylation level of PKA substrates (Fig. 7A). Interestingly, PKA 246	
stimulation caused an increase in cell surface expression of CLDN1 but no increase in 247	
CLDN1-CD81 co-localization (Fig. 7B-C). In agreement with this data, no increase in HCV 248	
infection was observed after activation of PKA (Fig. 7D).  249	
Similar experiments were performed activating the PKA pathway by overexpression 250	
of a GPCR, through exogenous transfection of a plasmid encoding 5-HT6 in Huh-7 cells. The 251	
increased phosphorylation level of PKA substrates (Fig. 7E), suggested that the exogenous 252	
receptor is functional and able to activate the PKA downstream pathway. As observed after 253	
PKA transfection, overexpression of 5-HT6 led to an increase in CLDN1 cell surface 254	
expression (Fig. 7F), also observed upon SB258585 treatment (Fig. 7G). However, this 255	
increase in CLDN1 cell surface localization did not correlate with an increase in CLDN1-256	
CD81 co-localization (Fig. 7H) or HCV infectivity (Fig. 7I).  257	
Together, these data strongly suggest that PKA regulates CLDN1 localization at the 258	
cell surface. However, its activation does not seem to be sufficient to mediate CLDN1 259	
interaction with CD81, which is necessary for HCV entry. Similarly, an increase of CLDN1 260	
cell surface expression without modification of CLDN1-CD81 interaction and HCV infection 261	
was observed after over-expression of CLDN1 (Fig. 7J-L). The failure in enhancing HCV 262	
infection upon CLDN1 overexpression is in accordance with previous data (5). Together, 263	
these results suggest that decreasing CLDN1 at plasma membrane strongly impacts HCV 264	
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entry, while increasing CLDN1 alone has no effect, probably due to a lack of recruitment to 265	
its main partner CD81.  266	
One potential explanation for the failure in increasing CLDN1-CD81 co-localization 267	
could be a limited availability of endogenous CD81. To address this hypothesis, we 268	
overexpressed this tetraspanin concomitantly with the GPCR 5-HT6. However, no 269	
enhancement of HCV infection was observed (Fig. 8A), suggesting that increasing the 270	
available quantity of both co-receptors was not sufficient to enhance their interaction and 271	
consequently viral entry.  272	
EGFR signaling has been described as important for CLDN1-CD81 interaction (30, 273	
31). To verify if our phenotype was due to an insufficient activation of this receptor and its 274	
downstream pathway, we treated Huh-7 with EGF. Although the stimulation induced the 275	
phosphorylation of EGFR and thus its activation (Fig. 8B), no enhancement of infectivity, but 276	
rather a slight decrease, was observed in our hands after increase of cell surface CLDN1 277	
induced by transfection of 5-HT6 GPCR (Fig. 8C). Therefore, an additional signal upstream 278	
of EGFR is likely necessary to relocalize CLDN1 to the site of interaction with CD81. 279	
 280	
The C-terminal region of CLDN1 is not involved in PKA-mediated inhibition. 281	
Predicted phosphorylation sites in the cytosolic domains of CLDN1 are only present in 282	
the C-terminal region of CLDN1 (32) and could be responsible for its localization. A mutant 283	
where the cytosolic C-terminus of CLDN1 was deleted has previously been described to 284	
remain functional for HCV entry (5). We therefore used this mutant to determine whether the 285	
effect of 5-HT6 activation antagonists is maintained when CLDN1 C-terminus region is 286	
deleted. For this, we generated a CRISPR/Cas9 CLDN1 KO cell line (Fig. 9A-B), and we re-287	
expressed a wild type or a C-terminal deleted CLDN1 (ΔCter) in this cell line (Fig. 9C-D). 288	
After verification that the transfection level and the surface localization of the two constructs 289	
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were comparable (Fig. 9C), we infected the cells with HCV in the presence or absence of 290	
SB258585. As shown in Fig. 9D, the absence of the C-terminus of CLDN1 did not alter the 291	
sensitivity of HCV infection to SB258585 or H89, suggesting that CLDN1 C-terminal 292	
cytosolic tail is not a direct target for PKA activity and is not required for its recycling.  293	
 294	
DISCUSSION 295	
HCV entry is a highly complex multi-step process involving a series of cellular 296	
proteins. Trafficking of these entry factors provides an additional level of complexity in the 297	
regulation of HCV entry. Here, by screening a chemical compound library, we identified the 298	
antagonist of 5-HT6 SB258585 as a novel inhibitor of HCV entry process. This drug, as well 299	
as another 5-HT6 antagonist SB399885, with which it shares similarities in structure, inhibits 300	
a post-binding step of HCV entry in a 5-HT6 independent manner. These two drugs induced a 301	
decrease in recycling of HCV entry co-receptor CLDN1 and its co-localization with CD81. 302	
The resulting reduction of CLDN1-CD81 interaction, known to be critical for HCV 303	
internalization, likely explains the drop of HCV infectivity. Treatment with these drugs 304	
showed a reduction in PKA activity and the involvement of this kinase-related pathway was 305	
confirmed to regulate CLDN1 localization and HCV late entry step. 306	
The attempt to detect 5-HT6 in liver biopsies and hepatocytes was unsuccessful. This 307	
failure in detecting 5-HT6 mRNA is supported by other reports (33). In addition, SB258585 308	
and SB399885 are supposed to inhibit 5-HT6 in a highly specific way at nanomolar 309	
concentrations. Therefore, the fact that in our hands the inhibition is only observed at 310	
micromolar concentrations supports the idea of an effect on another target, for which the drug 311	
shows less affinity. However, although the major target of these drugs in our model is 312	
unlikely to be 5-HT6, these chemical compounds inhibit PKA activity, suggesting an 313	
inhibitory effect on one or several other GPCRs likely associated to a Ga stimulatory protein. 314	
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According to Stitch 5.0 prediction (17), SB258585 shows an affinity for other 5-HT receptors, 315	
including the GPCR coupled to Gas 5-HT7, recently shown to play a role in liver fibrosis 316	
(33). Unfortunately no data are available concerning SB399885, although the common 317	
structure could suggest similar low-affinity targets. 318	
PKA likely controls the export of CLDN1. Indeed, a down-regulation of PKA activity 319	
reduces the cell surface expression of CLDN1, whereas its activation shows a direct increase 320	
of this tight junction protein at cell surface, confirming a direct correlation between PKA 321	
pathway and CLDN1 subcellular localization. The 5-HT6 receptor is a GPCR associated with 322	
a G alpha stimulatory protein, known to activate the PKA pathway (34). Therefore, it is not 323	
surprising that its overexpression stimulates PKA signaling and the export of the tight 324	
junction protein CLDN1, similarly to what happens upon direct PKA transfection or 325	
activation. Therefore, this experiment reinforces the hypothesis of a role for GPCRs in 326	
regulating PKA signaling in hepatocytes. This is in line with a previous report showing that 327	
PKA inhibitors affect HCV entry (29).  328	
Activation of the PKA pathway either by forskolin treatment, or by overexpression of 329	
the exogenous GPCR 5-HT6, or by overexpression of PKA catalytic subunit itself, increased 330	
CLDN1 export at the surface or rescued its surface localization in cells treated with 331	
SB258585. However, this was not sufficient to increase the basal level or to rescue HCV 332	
infection. Similarly, over-expression of CLDN1 led to an increase in CLDN1 expression at 333	
the cell surface without increasing HCV entry. In our case, in addition to analyzing CLDN1 334	
expression at the cell surface and HCV infection, we also monitored CD81-CLDN1 co-335	
localization, which was not rescued despite re-export of CLDN1 at the cell surface. Thus, 336	
there seems to be a disconnect between the level of CLDN1 expressed at the cell surface and 337	
CD81-CLDN1 interaction. These observations are in accordance with Farquhar’s work (29), 338	
where treatment with forskolin did not enhance HCVcc entry. Since CLDN1 interaction with 339	
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the tetraspanin CD81 is necessary to mediate HCV endocytosis (6, 7), this could explain the 340	
lack of rescue of HCV infection. The reason why CLDN1-CD81 co-localization is not 341	
restored upon PKA activation remains unclear. One possibility could be that in rescue 342	
experiments, despite the restoration of cell-surface expression of CLDN1, CD81 is no longer 343	
available to interact with CLDN1. The interaction between these two proteins is described to 344	
be regulated by the EGF receptor through HRas signaling (30, 31). However, neither 345	
overexpression of CD81 concomitantly with the GPCR 5-HT6, nor EGF stimulation restored 346	
the phenotype. This suggests that an additional signal upstream of EGFR is needed to target 347	
CLDN1 to the site of interaction with CD81. Further investigations are therefore required to 348	
better characterize the nature and the dynamics of the interaction between CLDN1 and CD81. 349	
However, we cannot exclude that this defect in HCV late entry step is not only due to the 350	
decreased interaction between CLDN1 and CD81. In addition to its involvement during 351	
exocytosis, there are in fact evidences of a role for cAMP/PKA pathway during endocytosis 352	
(reviewed in (35)). Therefore, the defect in HCV entry could not only be associated to 353	
CLDN1 localization change, but also to a general perturbation of the membrane trafficking, 354	
directly impacting HCV endocytosis. Further investigations are needed in order to elucidate 355	
the mechanism connecting PKA pathway activation and endocytosis, necessary to better 356	
clarify its additional involvement in HCV entry. 357	
Regulation of CLDN1 trafficking in hepatocytes remains poorly characterized. 358	
However, the CLDN1 C-terminal cytosolic tail presents several potential sites of post-359	
translational modification, including phosphorylation and ubiquitination, which could 360	
potentially play a role in its trafficking (36). Indeed, other reports indicate a role for the 361	
phosphorylation of CLDN1 cytosolic tail in the regulation of its subcellular localization in 362	
non-hepatic cells (37–39), or through a competition between phosphorylation and 363	
ubiquitination (40), as described for other members of the CLDN family (41, 42). However, 364	
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in our experimental work, the absence of the C-terminus of CLDN1 did not alter the 365	
sensitivity of HCV infection to 5-HT6 and PKA antagonists, excluding a role for a direct 366	
phosphorylation on CLDN1. Therefore, an additional, as of yet unidentified, intermediate 367	
protein likely phosphorylated by PKA is probably involved in regulation of CLDN1 368	
localization in the hepatocyte. However, cAMP/PKA pathway activation has been shown to 369	
stimulate exocytosis of several proteins towards both apical and basolateral surface in 370	
hepatocytes (reviewed in (35)), suggesting a conserved mechanism of export. 371	
Several compounds targeting other GPCRs were identified as HCV inhibitors in our 372	
screen. Previous studies described antihistamines, neuroleptic drugs and other ligands of 373	
GPCRs as inhibitors of HCV entry (16, 43, 44). In the future it would be interesting to test if 374	
the viral resistance mutations against any of these drugs eventually confer cross-resistance to 375	
piperazinylbenzenesulfonamides. Moreover, the identification of compounds targeting 376	
GPCRs in HCV screens could be in accordance with data from a recent chemical compound 377	
screen performed on Ebola and Marburg viruses, identifying the involvement of several 378	
antagonists of GPCRs, including 5-HT receptors, as inhibitors of a post-binding step of viral 379	
entry (45). In addition, connections between 5-HT receptors and viral infections have already 380	
been documented for several viruses, especially post-binding steps of viral entry as for 381	
reovirus, JC polyomavirus, chikungunya virus and mouse hepatitis virus (46–49). Several 382	
chemical compounds targeting 5-HT receptors were identified as HCV inhibitors in other 383	
HCS screens (50, 51). This suggests that a possible common mechanism, potentially affected 384	
by drugs targeting 5-HT receptor, might be used by different viruses. In this context, CLDN1 385	
might not be the only protein whose trafficking is altered by modulation of 5-HT pathway. 386	
Interestingly, in immune cells treated with an inhibitor of 5-HT uptake, HIV entry receptor 387	
and co-receptor were also observed to be down-regulated at the cell surface (52); however, 388	
the mechanism was not investigated. Further studies are necessary in order to better clarify if 389	
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there is actually a common pathway influencing the entry of all these viruses that could 390	
represent a potential drug target for wide-range antiviral development. 391	
In summary, we identified SB258585 and SB399885, antagonists of 5-HT6 receptor, 392	
as inhibitors of a post-binding step of HCV entry. Although we confirmed the absence of 5-393	
HT6 in liver and hepatic cells, we proved an inhibition of PKA activity as a consequence of 394	
the treatment, suggesting an off-target effect of these drugs on another GPCR. We thus 395	
confirmed an involvement of PKA in a post-binding step of HCV entry, showing that 396	
modulation of PKA activity regulates CLDN1 localization, through regulation of CLDN1 397	
recycling towards the cell surface. We thus suggest a role for PKA in the liver, as a regulator 398	
of CLDN1 export, which affects the HCV entry process influencing viruses of the six major 399	
genotypes. Finally, our work reinforces the hypothesis of a common pathway shared by 400	
several enveloped viruses, involving PKA-dependent signaling in late steps of viral entry. 401	
MATERIAL AND METHODS 402	
Cell culture. Huh-7 and Huh-7.5 cells have been previously described (53, 54) and were 403	
cultured at 37°C with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) 404	
supplemented with 10% fetal bovine serum (FBS). Experiments were performed in DMEM 405	
supplemented with 5% FBS. Huh-7 and Huh-7.5 cells were authenticated by the company 406	
Multiplexion, performing a Multiplex human cell line Authentication Test (MCA) as 407	
described at www.multiplexion.de. 408	
For experiments using forskolin and EGF, cells were preincubated during 2h in serum-free 409	
medium before incubation with the compound. DMEM, Opti-MEM, phosphate-buffered 410	
saline (PBS), goat serum, and FBS were purchased from Life Technologies. PHH were 411	
purchased from Biopredic and cultured at 37°C in supplemented Hepatocyte Basal Medium 412	
(Clonetics™ HCM™ BulletKit™, Lonza). 413	
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Viruses. Cell culture derived HCV (HCVcc) were produced by electroporation of Huh-7 cells 414	
with in vitro transcribed RNA of a modified JFH1 plasmid kindly provided by T. Wakita 415	
(National Institute of Infectious Diseases, Tokyo, Japan) (11). This modified JFH1 bears 416	
some titer-enhancing mutations and the reconstitution of the A4 epitope in E1 (10). Sequence-417	
confirmed virus stocks of JFH1-based Core-NS2 HCV recombinants were previously 418	
generated as described (21–27). 419	
Antibodies. Anti-HCV E1 mouse monoclonal antibody (MAb) A4 was produced in vitro 420	
using a MiniPerm apparatus (Heraeus) following the manufacturer’s protocol. Anti-CD81 421	
MAb (5A6) was kindly provided by S. Levy (Stanford University). Anti-SRB1 antibody 422	
C1671 was kindly given by A. Nicosia (OKAIROS, Italy). Anti-CLDN1 (OM 8A9-A3) MAb 423	
has been previously described (55). Anti Phospho-(Ser/Thr) PKA Substrate (9621) and anti-424	
HA tag (C29F4) and anti-Phospho-EGFR (Tyr1068)(1H12) mouse mAb (2236) 425	
were supplied from Cell Signaling Technology. Anti-EGFR (cocktail R19/48), anti-OCLN 426	
(OC-3F10) and anti-CLDN1 (51-9000) were purchased from Life Technologies. Anti-b-427	
tubulin (T5201), anti-HA tag (16B12), anti E-cadherin (AF648), anti-TGN46 (AHP500G), 428	
anti-GM130 (610822) and anti-ERGIC53 (ALX-804-602) antibodies were obtained from 429	
Sigma, Covance, R&D Systems, AbD Serotec, BD Biosciences and Enzo Life Sciences, 430	
respectively. Anti-rat and anti-mouse PE-coupled antibodies were supplied by BD 431	
Biosciences. Anti-Mouse Cy3, anti-Mouse Alexa 488, Anti-Rabbit Alexa647, anti-Mouse 432	
HRP and anti-Rabbit HRP were purchased from Jackson ImmunoResearch. Goat anti-rat and 433	
anti-mouse APC-coupled antibodies as well as anti-goat Alexa488, anti-rat Alexa555, anti-434	
sheep Alexa488 and anti-human Alexa488 coupled antibody were supplied by Life 435	
Technologies.  436	
Chemicals. SB258585 hydrochloride (sc-361339), SB399885 hydrochloride (sc-204264), 437	
H89 dihydrochloride (sc-3537) and forskolin (sc-3562) were purchased from Santa Cruz 438	
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Biotechnology. Bafilomycin A, proteinase K, DAPI and Puromycin dihydrochloride from 439	
Streptomyces alboniger were obtained from Sigma Aldrich. Mowiol was purchased from 440	
Calbiochem. Dimethyl sulfoxide (DMSO), Streptavidin−Agarose beads from Streptomyces 441	
avidinii and bafilomycin A1 were obtained from Sigma Aldrich. EGF, EZ-link Sulfo-NHS-442	
SS-Biotin, Dynabeads® Sheep Anti-Rat IgG and Hoechst 33342 were purchased from Life 443	
Technologies.  444	
Primer list.	CLDN1-crispR-F: 5’-CACCGCTTCATTCTCGCCTTCC-3’; CLDN1-crispR-R: 445	
5’-AAACGGAAGGCGAGAATGAAGC-3’; CLDN1-R: 5’-446	
GTGGATCCTCACACGTAGTCTTTCCCGC-3’; CLDN1-F: 5’-447	
TTAAGCTTGCCACCATGGCCAACGCGGGGCTGC-3’; 448	
CLDN1-DCter-R: 5’-GTGGATCCTCAACAGGAACAGCAAAGTAGGG-3’;  449	
Plasmids. pX459-CLDN1 was generated by insertion of the described RNA guides in 450	
pSpCas9(BB)-2A-Puro (PX459) (Addgene). pcDNA3.1-CD81-YFP was generated by 451	
insertion of YFP sequence in pcDNA3.1-CD81 vector. pCDNA3.1-CLDN1 and pCDNA 3.1-452	
CLDN1 DCter were generated by amplification of CLDN1 human cDNA contained in 453	
pCMV6-Ac vector (OriGene) by using CLDN1-F and CLDN1-R or CLDN1- DCter-R 454	
primers respectively and inserted into pCDNA3.1(+) (Invitrogen) by digestion with HindIII 455	
and BamH1. HTR6 N-terminus 3xHA-tagged plasmid was purchased from UMR cDNA 456	
Resource Center University of Missouri-Rolla (HTR060TN00) and PRKACA ORF 457	
mammalian expression plasmid C-HA tag from Sino Biological Inc. (HG11544-CY). 458	
Human biopsies. For mRNA expression analysis of 17 normal tissue samples (Ambion), 459	
total RNA (500 ng) was reverse transcribed using SuperScript™ II Reverse Transcriptase 460	
(Invitrogen) and random hexamer. Using Taqman gene expression assay (Life Technologies) 461	
for 5HT-6 gene (Hs00168381_m1) and RPLP0 (Hs99999902_m1) as control, real-time PCR 462	
amplifications were run in duplicate using LightCycler 480 Probe Master (Roche) and were 463	
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performed on the LightCycler 480 Instrument II (Roche) according to the MIQE guidelines 464	
(56). Samples that lacked either a template or reverse transcriptase were used as controls. The 465	
relative expression of each gene was calculated according to the 2-ΔCt quantification method 466	
where ΔCt value was determined by subtracting the average Ct value of the target gene from 467	
the average Ct value of the control gene. 468	
HCS analysis. 1,120 biologically active compounds from Tocriscreen Total library at 10 mM 469	
in pure DMSO were dispensed in 384-well µClear black plates (Greiner bio-one Cat. 781091) 470	
using the nanoliter acoustic liquid handler Echo 550® (LabCyte). 16 wells containing pure 471	
DMSO were used as controls. Eight hundred Huh-7 cells were seeded in 30 µl in 384-well 472	
plates and incubated with each compound respectively at a final concentration of 1, 10 or 20 473	
µM at 37°C and 5% CO2. Sixteen hours later, cells were infected with 30 µl of HCVcc at a 474	
MOI of 0.4 and incubated at 37°C and 5% CO2. After 72 h, 40µl the supernatant was 475	
harvested on a second set of 384-well µClear black plates containing twelve hundred Huh-7 476	
cells with an automated liquid handler Bravo (Agilent) and incubated at 37°C and 5% CO2 for 477	
48 h. The infected cells in the two sets of 384-well plates were fixed for 30 minutes using 478	
formalin solution, neutral buffered, 10% (Sigma-Aldrich, Cat. HT5014) at room temperature. 479	
Cells were then permeabilized with 0.1% Triton X-100 in PBS for 3 minutes at room 480	
temperature and HCV infected cells were revealed by immunofluorescence with anti-E1 481	
antibody (MAb) A4 (1:1000 dilution) for 30 minutes at room temperature. Goat anti-mouse 482	
Alexa-488 was used as a secondary antibody (1:500 dilution), while nuclei were labeled with 483	
DAPI (1:500 dilution) for 30 minutes at room temperature. Two fields per well were acquired 484	
using the 20X objective (NA 0.45) using excitation laser (Ex) at 405 nm and emission filter 485	
(Em) at 450 nm for DAPI detection and Ex at 488 nm and Em at 540 nm for virus detection. 486	
on an automated confocal microscope InCell 6000 Analyzer (GE Healthcare). Images were 487	
analyzed using a dedicated image analysis performed on the Columbus Software allowing 488	
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automated quantification of the number of cells and the percentage of infected cells per well. 489	
Compounds reducing the cell number by more than 35% compared to the average of DMSO 490	
control wells were considered toxic and discarded. Compounds decreasing the percentage of 491	
infection of at least 45%, whose effect was confirmed upon re-infection, were identified as 492	
positive hits. Image analysis parameters of Columbus software are available upon request. 493	
JFH1 infection assay. JFH1-HCVcc infection was quantified as previously described (10).  494	
Core-NS2 HCV recombinant infection assay. Huh7.5 cells were plated at 7000 cells/well in 495	
PDL coated 96 well plates. The following day, four replicates of the described Core-NS2 496	
HCV recombinants were mixed with different concentrations of SB258585 in DMEM 497	
supplemented with 10% FBS, along with 8 replicates of virus only without SB258585, and 498	
added to Huh7.5 cells for 3 h. Following this incubation, the cells were washed and full 499	
medium was added. After a total of 48 h post virus inoculation, the numbers of focus forming 500	
units were visualized by HCV-specific immunostaining using NS5A antibody, 9E10 (24). 501	
Counting was automated using an ImmunoSpot Series 5 UV Analyzer as described (57) and 502	
the counts were normalized to the mean count of virus only. 503	
PHH infection. PHH (Biopredic) were inoculated for 3 h with a cell culture adapted JFH1 504	
strain in the presence of increasing concentrations of SB258585 and infection was measured 505	
by quantification of intracellular HCV RNA 24 h post-inoculation, as previously described 506	
(20). 	507	
HCVpp and infection assays. HCVpp bearing E1E2 glycoproteins of strain JFH1 (genotype 508	
2a) were produced as previously described (58).  RD114pp were produced using a plasmid 509	
encoding the feline endogenous virus RD114 glycoprotein (59). Huh-7 cells were incubated 510	
with pseudotyped particles for 3h at 37°C, concomitantly with increasing concentrations of 511	
drugs. At 48h post-infection, firefly luciferase (FLuc) assays were performed following the 512	
manufacturer’s protocol (Promega). 513	
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HCVcc entry assay. After 2 h of JFH1-HCVcc attachment at 4°C, Huh-7 cells were washed 514	
and shifted to 37°C to induce viral internalization. Each drug was added every 15 minutes 515	
during a 2 h kinetic. Proteinase K (50 µg/ml) and bafilomycin A (25 nM) were included as 516	
controls respectively for an early and a late step of viral entry. When treated with proteinase 517	
K, cells were washed in cold PBS and incubated with proteinase K for 1 h at 4°C under gentle 518	
agitation, before washing them again and adding fresh medium at 37°C. The infection rate 519	
was calculated by IF 30 h later and each time point was normalized to the corresponding 520	
DMSO condition. 521	
Adenovirus infection. A recombinant adenovirus (AdV) expressing a green fluorescent 522	
protein was generated as previously described (10). Huh-7 cells were inoculated with the 523	
virus for 2 h at 37°C concomitantly with increasing concentration of SB258585 and cultured 524	
for 24 h at 37°C. AdV infections were scored using an Axioplan2 epifluorescence microscope 525	
(Zeiss) after fixation and nuclei staining with Hoechst. 526	
Viability assay. Huh-7 cells were incubated for 2 h with increasing concentrations of the 527	
indicated compound. A MTS assay was performed 28 h post-treatment, according to the 528	
manufacturer’s protocol (Promega) in order to evaluate cell viability. 529	
Immunofluorescence and quantification of CLDN1 co-localization with markers of 530	
subcellular compartments. Huh-7 cells previously seeded on coverslips were treated with 531	
the indicated compounds. After treatment cells were fixed for 30 minutes with 3 % 532	
paraformaldehyde. Cells were permeabilized during 5 minutes with 0.1 % Triton X-100 and 533	
saturated for 30 minutes with PBS containing 10 % goat serum. Primary antibodies were 534	
incubated during 30 minutes in PBS-goat serum. After three washes, secondary antibodies 535	
and DAPI were added during 30 minutes. After three more washes, coverslips were mounted 536	
on glass slides using Mowiol. Images were taken using a Zeiss-LSM880 or a Zeiss-LSM780 537	
confocal microscope, with a 63X oil objective. Pearson correlation coefficients were 538	
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calculated using the Fiji coloc2 plugin on regions of interest (ROIs) from single cells, 539	
designed on the basis of cell compartment labeling. Each experiment was repeated at least 540	
three times and at least 40 cells for each condition were quantified. 541	
Quantification of CD81-CLDN1 colocalization. Huh-7 cells were seeded on coverslips and 542	
treated with the indicated inhibitor. After treatment cells were fixed for 30 minutes with 3 % 543	
paraformaldehyde. Cells were incubated for 30 minutes with PBS containing 10 % goat 544	
serum. Primary antibodies diluted in PBS-goat serum were added during 30 minutes. After 545	
three washes, secondary antibodies and Hoechst were added for another 30 minutes. After 546	
three more washes, coverslips were mounted on glass slides using Mowiol. Images were 547	
taken using a Zeiss-LSM880 confocal microscope, with a 63X oil objective. Pearson 548	
correlation coefficients were calculated using the Fiji coloc2 plugin on regions of interest 549	
(ROIs) from single cells, designed on the bases of CD81 surface labeling. Each experiment 550	
was repeated at least three times and a total of at least 40 cells for each condition were 551	
quantified.  552	
Flow cytometry. Huh-7 cells treated with the indicated compound for the indicated period of 553	
time or siRNA transfected Huh-7 cells were incubated for 30 minutes at 4°C with the 554	
indicated primary antibody diluted in cold PBS supplemented with 2 % BSA. After three 555	
washes with cold PBS-BSA, cells were incubated for 30 minutes at 4°C with secondary 556	
antibodies. After three more washes, cells were incubated for another 30 minutes with cold 557	
PBS supplemented with 2 mM EDTA and then resuspended and fixed with a formalin 558	
solution at a final concentration of 1.5 % formalin. For PKA-HA labeling, cells were 559	
permeabilized for 30 minutes with 5% saponin and each following step was performed in the 560	
presence of 5% saponin. Cells were analyzed using a BD FACSCANTO II Flow Cytometer. 561	
Analyses were performed using Weasel and FlowJo softwares.  562	
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Surface biotinylation and endocytosis. Biotinylation assay was performed as previously 563	
described (60). A western blot was performed in order to detect CLDN1. Proteins were 564	
resolved by SDS-PAGE and transferred on a nitrocellulose membrane. The membrane was 565	
immunoblotted with the indicated primary antibody, followed by peroxidase-coupled 566	
secondary antibodies. Proteins were detected using a LAS3000 machine (Fuji). 567	
cDNA transfection. Huh-7 cells were seeded in 24-well plates and transfected with 250 ng of 568	
DNA using TransIT®-LT1 Transfection Reagent, according to the manufacturer’s protocol. 569	
Either treatment followed by FACS analyses or infection experiments were performed 48 h 570	
post-transfection. 571	
RNA extraction and qRT-PCR. RNA was extracted from Huh-7 cells using the 572	
NucleoSpin® RNA extraction kit (Macherey Nagel), and 2 µg were used for cDNA 573	
retrotranscription using the High-Capacity cDNA Reverse Transcription Kit (Life 574	
Technologies). Taqman® predesigned gene expression assay approach (Applied Biosystems) 575	
using a TaqMan FAM-MGB probe (Hs00168381_m1) was used to perform a qPCR in order 576	
to quantify HTR6 (50 cycles). RPLP0 (Hs00420895_gH) was used as a housekeeping gene. 577	
DCt values were calculated according to the formula: Ct(HTR6)-Ct(RPLP0).  578	
CLDN1-KO cell line. Huh-7 cells were seeded in 6-well plates and transfected with 1 µg of 579	
pX459-CLDN1 plasmid using the Trans-IT LT1 reagent (Mirus) according to the 580	
manufacturer’s protocol. Three days after transfection cells were selected using DMEM 581	
supplemented with 2 µg/ml of puromycin. Selection was removed after 4 days and cells were 582	
cultured in complete DMEM medium. Knocking out was checked both by Western Blotting 583	
and flow cytometry analysis. In order to remove the residual population of cells still 584	
expressing CLDN1, a selection was performed using Dynabeads® Sheep Anti-Rat IgG after 585	
labeling of the cells with anti-CLDN1 OM 8A9-A3 antibody. 586	
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Quantification and statistical analysis. Data are presented as means ± standard error of the 587	
mean (SEM), except when specified differently. Statistical parameters and analyses are 588	
reported in the Fig. legends n represents the number of independent experiments. Where 589	
indicated, asterisks denote statistical significance as follows: *p < 0.05 and **p < 0.01, 590	
***p<0.001, ****p<0.0001, ns=non-significant. Statistical analyses were performed using 591	
GraphPad Prism 7.  592	
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 811	
 812	
FIGURE LEGENDS 813	
Figure 1: Identification of the 5-HT6 antagonist SB258585 as a new inhibitor of the 814	
HCV life cycle. (A-C) A HCS screen with a library of 1120 chemical compounds was 815	
performed at three different concentrations (1 µM, 10 µM and 20 µM). Dot-plots show the 816	
distributions of the populations on the bases of cell number and percentage of HCVcc JFH1 817	
(genotype 2a) infected cells at the indicated concentrations. Each dot represents one 818	
compound. Green lines represent the average values corresponding to DMSO control wells. 819	
Red lines represent the selected cut-offs, determining the positive hits (light red squares). (D) 820	
Summary of the positive hits selected according to the cut-offs, at each concentration. The red 821	
circle indicates compounds confirmed as positive hits for at least two concentrations. (E) 822	
Graph showing the percentage of HCVcc infection corresponding to the wells treated with 823	
chemical compounds targeting in a more or less specific way 5-HT6, normalized to the mean 824	
of the DMSO control wells at each concentration. The green line corresponds to the 825	
compound SB258585 hydrochloride. (F) Wells corresponding to DMSO and SB258585 for 826	
each concentration of the screen. Nuclei are shown in blue, HCV E1 staining in green. 827	
 828	
Figure 2: SB258585 inhibits HCV infection, modulating PKA in a 5-HT6 independent 829	
manner. (A) Huh-7 cells were treated with SB258585 at different concentrations for 2 h 830	
prior, during or after JFH1 HCVcc incubation, following the kinetics schematized. Infection 831	
was quantified at 30 h post-infection by immunofluorescence. (B) Huh-7 cells were treated 832	
	 30	
with the drug 2 h, followed by 28 h of rest. A MTS assay was performed in order to evaluate 833	
the cell toxicity. (C) Quantification of 5-HT6 mRNA level by qRT-PCR in 17 tissues from 834	
human biopsies. (D) Huh-7 cells were treated for 2 h with DMSO, H89 (10 µM), SB258585 835	
(100 µM) or SB399885 (100 µM). A representative western blot from n=3 and relative 836	
quantification of total phosphorylation of PKA substrates normalized to the loading control b-837	
tubulin are presented. Results are presented as means ± standard error of the mean (SEM) for 838	
n=3 (A, B, D). One-way (B, D) or Two-way ANOVA (A) respectively followed by Dunnett 839	
or Bonferroni post-test were performed as statistical tests. *, P < 0.05; **, P < 0.01; ***, P < 840	
0.001; ****, P < 0.001. 841	
 842	
Figure 3: Piperazinylbenzenesulfonamides inhibit a late step of HCV entry in all the 843	
major genotypes. (A) Huh-7 cells were treated for 3 h with SB258585 at different 844	
concentrations concomitantly with JFH1 HCVpp or RD114pp incubation. At 48 h post-845	
infection, cells were lysed and luciferase activity was measured in order to quantify the 846	
infection. (B) Huh-7 cells were incubated for 2 h with SB258585 at different concentrations 847	
along with GFP-Adenovirus. The percentage of infection was determined by quantifying 848	
GFP-positive cells at 24 h post-infection. (C) Primary human hepatocytes (PHHs) were 849	
treated for 2 h with SB258585 at different concentrations, in addition to JFH1 HCVcc. 850	
Infection was quantified by RTqPCR at 24 h post-infection. (D) Huh-7.5 cells were treated for 851	
3 h with SB258585 in addition to JFH1-based HCV genotype 1-6 recombinant viruses with 852	
strain specific core-NS2. Infection was quantified by immunofluorescence at 48 h post-853	
inoculation. Error bars represent SD. (E) After 1 h of viral attachment at 4°C, Huh-7 cells 854	
were shifted at 37°C and treated with SB258585 at the indicated concentrations, following 855	
15-minute kinetics during 2 h. Proteinase K (50 µg/ml) and bafilomycin A (25 nM) were used 856	
as controls respectively for early and late entry steps. Infection was quantified at 30 h post-857	
	 31	
infection by immunofluorescence and each time point was normalized to the corresponding 858	
DMSO condition. (F) Chemical structure of SB258585 and SB399885. (G) Huh-7 cells were 859	
treated with SB399885 at different concentrations for 2 h prior, during or after JFH1 HCVcc 860	
incubation, following the kinetics schematized. Infection was quantified at 30 h post-infection 861	
by immunofluorescence. (H) Huh-7 cells were treated with SB399885 2 h, followed by 28 h 862	
of resting. A MTS assay was performed in order to evaluate the cell toxicity. (I) After 1 h of 863	
viral attachment at 4°C, Huh-7 cells were shifted at 37°C and treated with SB399885 at the 864	
indicated concentration, following 15-minute kinetics during 2 h. Proteinase K (50 µg/ml) and 865	
bafilomycin A (25 nM) were used as controls respectively for early and late entry steps. 866	
Infection was quantified at 30 h post-infection by immunofluorescence and each time point 867	
was normalized to the corresponding DMSO condition. Results are presented as means ± 868	
standard error of the mean (SEM) for n=3 (A-D, G-H) and n=2 (E, I). PHH results are 869	
presented as mean of triplicates ± SEM for two independent experiments. One-way (B, C, H) 870	
or Two-way ANOVA (A, G) respectively followed by Dunnett or Bonferroni post-test were 871	
performed as statistical tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.001; ns, 872	
non significant. 873	
 874	
Figure 4: SB258585 alters CLDN1 recycling causing its intracellular accumulation. (A) 875	
Huh-7 cells were treated for 2 h with DMSO or increasing concentrations of SB258585. Cell 876	
surface expression of CD81 and CLDN1 was analyzed by immunofluorescence. Images were 877	
taken using a Zeiss LSM-880 and 63X objective. (B) Pearson correlation coefficient (PCC) 878	
was calculated on cell surface ROIs from at least 40 different cells in each condition. (C) 879	
Huh-7 cells were treated for two hours with DMSO or increasing concentrations of SB258585 880	
and CLDN1 expression was analysed by flow cytometry. Curves from a representative 881	
experiment are shown. Mean fluorescent intensities relative to the DMSO-treated condition 882	
	 32	
are also presented. (D) Huh-7 cells were treated for two hours with DMSO or increasing 883	
concentrations of SB399885 and CLDN1 expression was analyzed by flow cytometry. (E) 884	
Huh-7 cells were incubated for the indicated periods with SB258585 (100 µM). CLDN1 885	
present at the cell surface was quantified by flow cytometry. (F) Huh-7 cells were treated for 886	
2 h with SB258585 (100 µM). The drug was then removed and replaced by DMEM for the 887	
indicated time. Cytometry analyses were performed to quantify CLDN1 at cell surface. Mean 888	
fluorescence intensities relative to the DMSO-treated condition are shown (D-F). (G) Huh-7 889	
cells were treated for 2 h with DMSO, SB258585 (100 µM), SB399885 (100 µM) or H89 (10 890	
µM). The total quantity of CLDN1 was assessed by Western Blot. b-tubulin was used as a 891	
loading control. (H) Huh-7 cells were treated for 2 h with DMSO, SB258585 (100 µM), or 892	
H89 (10 µM). CLDN1 subcellular localization was determined by immunofluorescence after 893	
membrane permeabilization. Images were taken at 63X objective. (I) TGN46 was stained 894	
concomitantly with CLDN1 and PCCs were calculated for intracellular CLDN1-TGN46 co-895	
localization for n>35 cells for each condition. (J) After surface biotinylation, Huh-7 cells were 896	
incubated at 37°C with DMSO or SB258585 (100 µM) for the indicated time. Biotin 897	
remaining at the cell surface was cleaved using glutathione. The amount of internalized 898	
CLDN1 was determined by western blotting after pull-down of biotin-labeled proteins with 899	
streptavidin-agarose beads. A representative western blot from n=3 is presented. All results 900	
are presented as means ± standard error of the mean (SEM) for n=3. One-way ANOVA (B-E, 901	
I) or Two-way ANOVA (F) respectively followed by Dunnett or Bonferroni post-test were 902	
performed as statistical tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.001. Scale 903	
bars = 30 µm. 904	
 905	
Figure 5: SB258585 does not alter the surface localization of the other main HCV entry 906	
factors. (A) Huh-7 cells were treated for two hours with DMSO or increasing concentrations 907	
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of SB258585. A surface biotinylation followed by a biotin immunoprecipitation was 908	
performed and a representative western blot against OCLN is shown. The quantity of 909	
biotinylated OCLN was determined using Fiji from western blots corresponding to n=3. (B-E) 910	
Huh-7 cells were treated for 2 h with DMSO or increasing concentrations of SB258585. 911	
CD81 (B), EGFR (C), SRB1 (D) and E-cadherin (E) expression were analyzed by flow 912	
cytometry. Curves from a representative experiment are shown. Mean fluorescence intensities 913	
relative to the DMSO-treated condition are presented as means ± SEM. All the results are 914	
presented as means ± SEM for n=3. One-way ANOVA followed by Dunnett post-test were 915	
performed as statistical tests. ns, non significant. 916	
 917	
Figure 6: Inhibition of PKA signaling pathway down-regulates HCV entry and CLDN1 918	
cell surface localization. (A) Huh-7 cells were treated 2 h with H89 at different 919	
concentrations. An MTS assay was performed 30 h post treatment in order to evaluate the cell 920	
toxicity of the compound. (B) Huh-7 cells were treated for 3 h with H89 at different 921	
concentrations along with JFH1 HCVpp and RD114pp. At 48 h post-infection, cells were 922	
lysed and luciferase activity was measured in order to quantify the infection. (C) Huh-7 cells 923	
were treated with H89 at different concentrations in accordance with the kinetics schematized, 924	
along with JFH1 HCVcc. Infection was quantified at 30 h post-infection by 925	
immunofluorescence. (D) After 1 h of viral attachment at 4°C, Huh-7 cells were shifted at 926	
37°C and treated with H89 (10 µM), following 15-minute kinetics during 2 h. Proteinase K 927	
(50 µg/ml) and bafilomycin A (25 nM) were used as controls respectively for early and late 928	
entry steps. Infection was quantified at 30 h post-infection by immunofluorescence and each 929	
time point was normalized to the corresponding DMSO condition. (E) Huh-7 cells were 930	
treated for 2 h with DMSO or H89 (10 µM). Cell surface CLDN1 was analyzed by flow 931	
cytometry. Curves from a representative experiment and mean fluorescence intensities 932	
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relative to the DMSO-treated condition are shown. Results are presented as means ± SEM for 933	
n=3 (A-C, E) and n=2 (D). Two-tailed Student’s T test (E), One-way (A) or Two-way 934	
ANOVA (B-C) respectively followed by Dunnett or Bonferroni post-test were performed as 935	
statistical tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.001. 936	
 937	
Figure 7: PKA activation increases CLDN1 localization at cell surface, without 938	
increasing HCV entry or CLDN1-CD81 co-localization. (A-D) Huh-7 cells were 939	
transfected with pcDNA or pcDNA-PRKACA for 48 h. Cells were treated for 2 h with 940	
DMSO, forskolin (20 µM) as indicated. (A) A representative western blot from n=3 is 941	
presented, in order to analyse the phosphorylation of PKA substrates. b-tubulin was used as a 942	
loading control and PKA transfection was checked by HA immuno-blotting. (B) Cytometry 943	
analysis was performed for quantifying CLDN1 cell surface localization and PKA-HA 944	
transfection. Mean fluorescence intensities relative to the DMSO-treated condition from n=3 945	
are shown. (C) CLDN1 and CD81 were analyzed by immunofluorescence and PCCs were 946	
calculated after confocal image acquisition on cell surface ROIs from at least 40 different 947	
cells in each condition. (D) Transfected cells were treated for 2 h with DMSO or forskolin (20 948	
µM), together with HCVcc. Infection was quantified at 30h post-infection by 949	
immunofluorescence. (E-I) Huh-7 cells were transfected for 48 h with pcDNA or pcDNA-5-950	
HT6. (E) A representative western blot from n=2 and relative quantification of total 951	
phosphorylation of PKA substrates normalized to the loading control b-tubulin are presented. 952	
HA-5-HT6 transfection was checked by HA immuno-blotting. (F-G). Cell surface CLDN1 953	
and HA-5-HT6 were immunolabeled and quantified by flow cytometry. Mean fluorescence 954	
intensities relative to the DMSO-treated condition are shown. (G) Transfected Huh-7 cells 955	
were treated 2 h with SB258585 (100 µM) before labeling for flow cytometry analyses. (H) 956	
CLDN1 and CD81 immunostaining followed by confocal microscopy allowed for the 957	
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calculation of PCCs on cell surface ROIs from at least 40 different cells in each condition. (I) 958	
Transfected Huh-7 cells were infected 2h with HCVcc. Infection was quantified at 30 h post-959	
infection by immunofluorescence. (J-L) Huh-7 cells were transfected for 48 h with pcDNA or 960	
pcDNA-CLDN1. Cell surface CLDN1 was immunolabeled and quantified by flow cytometry. 961	
Mean fluorescence intensities relative to the DMSO-treated condition are shown (J). CLDN1 962	
and CD81 immunostaining followed by confocal microscopy allowed for the calculation of 963	
PCCs on cell surface ROIs from at least 40 different cells in each condition (K). Transfected 964	
cells were infected with HCVcc 48 h post-transfection. Infection was quantified at 30 h post-965	
infection by immunofluorescence (L). Results are presented as means ± SEM for n=3 (C-D, 966	
H-I) or n=4 (B, F-G, J-L) independent experiments. Two-tailed Student’s T test (E-F, H-L) or 967	
Two-way ANOVA (B-D, G) followed by Bonferroni post-test were performed as statistical 968	
tests. *, P < 0.05; ***, P < 0.001; ns, non significant.  969	
 970	
Figure 8: Increase of CLDN1 localization at cell surface is not sufficient to increase HCV 971	
entry, neither upon CD81 over-expression nor EGF stimulation. (A) Huh-7 cells were 972	
transfected with pcDNA, HA-5-HT6, CD81-YFP alone or in combination as indicated. 48 h 973	
post-transfection cells were infected with JFH1-HCVcc. 30 hpi cells were fixed and infection 974	
rate was determined by IF. (B) After 2 h of starvation, Huh-7 cells were non-stimulated or 975	
stimulated 1 h with EGF (1 µg/ml). A western blot was performed to verify the activation of 976	
EGFR, through phosphorylation. b-tubulin was used as a loading control. (C) Huh-7 cells 977	
transfected 48 h with pcDNA, HA-5-HT6, CD81-YFP alone or in combination, after 2 h of 978	
starvation, were treated 1 h with EGF (1 µg/ml) and infected 2 h with JFH1-HCVcc 979	
concomitantly with EGF (1 µg/ml). 30 hpi cells were fixed and infection rate was determined 980	
by IF. Results are presented as means ± SEM for n=2 (A, C). One-way (A) or Two-way 981	
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ANOVA (C) respectively followed by Dunnett or Bonferroni post-test were performed as 982	
statistical tests. ns, non significant. 983	
 984	
Figure 9: Deletion of CLDN1 C-terminal region does not alter HCV sensitivity to 985	
SB258585 and H89. (A-D) Flow cytometry (A) and western blot (B) were performed on 986	
CLDN1 CrispR/CAS9 and control pX459 cells, in order to evaluate CLDN1 silencing. OCLN 987	
was used as a loading control for the western blot. (C-D) CLDN1 CrispR/CAS9 cells were 988	
transfected respectively with pcDNA 3.1, CLDN1 WT or ΔCter. 48 h post-transfection cells 989	
were labeled for CLDN1 at the cell surface and analyzed by flow cytometry (C) or infected 990	
with JFH1-HCVcc (D). 30 hpi cells were fixed and infection rate was determined by IF. 991	
Results are presented as means ± SEM for n=3. Two-way ANOVA (D) followed by 992	
Bonferroni post-test was performed as statistical tests. ****, P < 0.001. 993	









